RESEARCH TRIANGLE PARK, N.C. – May 23, 2011 – Quintiles today announced the appointment of Frederic “Rick” Sax as Senior Vice President and Global Head of its Integrated Clinical Services division, which provides a suite of clinical trial services designed to speed the flow of high-quality clinical results to biopharmaceutical customers and add value to clinical development programs.
Sax is responsible for the business lines that comprise Integrated Clinical Services, including Central Laboratory, Cardiac Safety, Biostatistics, Regulatory Affairs, Medical Writing and Lifecycle Safety Services. He will leverage Quintiles’ suite of trial services to deliver operational efficiencies and cost savings for customers.
“Rick’s deep and broad experience in biopharma gives him a solid understanding of the challenges that our customers face in the New Health,” said Paula Brown Stafford, President of Quintiles Clinical Development. “He will help our customers navigate challenges and seize opportunities through the delivery of integrated clinical trial services that help customers reduce overall study costs, proactively manage quality, simplify trial management and accelerate development.”
Sax has nearly 20 years of experience in the biopharmaceutical industry. Most recently Sax served as Vice President of Clinical Design Strategies for AstraZeneca, leading the design of solutions to enhance the quality of program and trial design while driving efficiencies in cost, time and process. He has held executive-level positions at both AstraZeneca and Merck Research Laboratories, where he managed the successful development and registration of new therapies.
“My focus is on helping our customers realize the true value of partnering with Quintiles for multiple clinical trial services,” said Sax. “By combining Quintiles’ clinical monitoring and central laboratory services, for example, many of our customers have realized significant cost savings. Not all CROs can offer this breadth and depth of services—from clinical monitoring to regulatory submission, and I’m delighted to have the opportunity to lead Quintiles’ Integrated Clinical Services division.”
Prior to joining the biopharmaceutical industry, Sax served as an academic cardiologist. He graduated with a B.A. in Biology and Philosophy from Yale College, and an M.D. from Columbia University. Sax will be relocating with his family from Wilmington, Del., to North Carolina.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 20,000 engaged professionals in 60 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.